SCHEMBL2460596

SCHEMBL2460596

ClCn1c2ccccc2c2ccccc21

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.64
CYP2C19 P33261 1/20 0.64
CYP19A1 P11511 1/20 0.60
BACE1 P56817 2/20 0.52
KDM4E B2RXH2 3/20 0.50
FABP4 P15090 2/20 0.47
FABP5 Q01469 2/20 0.47
FABP3 P05413 1/20 0.47
P2RX4 Q99571 1/20 0.47
GPR3 P46089 1/20 0.46
DNM1 Q05193 2/20 0.46
ALDH1A1 P00352 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
HDAC6 Q9UBN7 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30038698 0.80 CYP1A2 (0.58) CYP1A2CYP2C19CYP19A1BACE1KDM4E
SCHEMBL1478604 0.80 CYP1A2 (0.58) CYP1A2CYP2C19CYP19A1BACE1KDM4E
SCHEMBL19009367 0.79 CYP1A2 (0.64) CYP1A2CYP2C19CYP19A1BACE1KDM4E
SCHEMBL9768532 0.78 CYP1A2 (0.70) CYP1A2CYP2C19CYP19A1BACE1KDM4E
SCHEMBL5134759 0.78 CYP1A2 (1.00) CYP1A2CYP2C19CYP19A1BACE1KDM4E
SCHEMBL13957035 0.77 CYP19A1 (0.86) CYP1A2CYP2C19CYP19A1P2RX4HDAC6
SCHEMBL2700703 0.77 FABP4 (0.56) CYP1A2CYP2C19CYP19A1FABP4FABP5
SCHEMBL541993 0.77 FABP4 (0.56) CYP1A2CYP2C19CYP19A1FABP4FABP5
SCHEMBL30007452 0.75 CYP19A1 (1.00) CYP1A2CYP2C19CYP19A1KDM4EP2RX4
SCHEMBL151053 0.75 CYP19A1 (1.00) CYP1A2CYP2C19CYP19A1KDM4EP2RX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109516946-A A method of preparing carbazole compound 上海交通大学 2019-03-26 CN disclosed
CN-104370801-B Carbazole compound and application thereof 东曹株式会社 2017-11-03 CN disclosed
US-20170298118-A1 METHODS FOR SCREENING ANTIBODIES SEATTLE GENETICS, INC. (US) 2017-10-19 US disclosed
US-9725500-B2 Methods for screening antibodies SEATTLE GENETICS, INC. (US) 2017-08-08 US disclosed
CN-104326968-B Carbazole compound and use thereof 东曹株式会社 2017-04-12 CN disclosed
EP-2542576-B1 METHODS FOR SCREENING ANTIBODIES SEATTLE GENETICS INC (US) 2016-04-20 EP disclosed
US-9278124-B2 Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods HALOZYME, INC. (US) 2016-03-08 US disclosed
CN-104370801-A Carbazole compound, and use therefor TOSOH CORP 2015-02-25 CN disclosed
CN-104326968-A Carbazole compound and use thereof TOSOH CORP 2015-02-04 CN disclosed
WO-2014062856-A1 HYPOXIA AND HYALURONAN AND MARKERS THEREOF FOR DIAGNOSIS AND MONITORING OF DISEASES AND CONDITIONS AND RELATED METHODS HALOZYME, INC. (US) 2014-04-24 WO disclosed
EP-2542576-A1 METHODS FOR SCREENING ANTIBODIES Seattle Genetics, Inc. (US) 2013-01-09 EP disclosed
US-20120322686-A1 METHODS FOR SCREENING ANTIBODIES SEATTLE GENETICS, INC. (US) 2012-12-20 US disclosed
WO-2011109308-A1 METHODS FOR SCREENING ANTIBODIES SEATTLE GENETICS, INC. (US) 2011-09-09 WO disclosed
US-4835312-A Production process of N-substituted amide compounds MITSUI CHEMICALS, INCORPORATED (JP) 1989-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170298118-A1 METHODS FOR SCREENING ANTIBODIES FCGR2A, FCGR3B, FCGR1A CYP1A2 4289/4885CYP2C19 4671/4885CYP19A1 3366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.